The estimated Net Worth of Ben Bronstein is at least $310 ezer dollars as of 27 June 2023. Ben Bronstein owns over 9,604 units of Aldeyra Therapeutics Inc stock worth over $174,855 and over the last 11 years he sold ALDX stock worth over $0. In addition, he makes $135,515 as Independent Director at Aldeyra Therapeutics Inc.
Sign up
Ben Bronstein ALDX stock SEC Form 4 insiders trading
Ben has made over 4 trades of the Aldeyra Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 9,604 units of ALDX stock worth $5,282 on 27 June 2023.
The largest trade he's ever made was buying 12,500 units of Aldeyra Therapeutics Inc stock on 7 May 2014 worth over $100,000. On average, Ben trades about 2,018 units every 238 days since 2014. As of 27 June 2023 he still owns at least 28,248 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Ben Bronstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ben Bronstein biography
Dr. Ben Bronstein M.D. serves as Independent Director of the Company. Dr. Bronstein is an independent consultant providing advisory services to companies in the life sciences industry. Prior to his consulting role, he was Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 29 years in entrepreneurial and management roles in life science companies and venture capital firms. Dr. Bronstein has founded or held senior management positions at several venture-backed life science companies including: Neuron Systems, Inc. (CEO), the predecessor company to Aldeyra Therapeutics, Inc.; BioSurface Technology, Inc., a regenerative medicine company; Peptimmune, Inc., an immunotherapeutics company (a spinout from Harvard and MIT); and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. Dr. Bronstein has served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School and as a founder and Senior Vice President of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the boards of directors of several privately held life science companies. He is also a member of the Scientific Advisory Committee of the Daedalus Fund of Weill Cornell Medicine from which he resigned (retired) effective January 2020. Dr. Bronstein received his M.D. and M.B.A. from Boston University. Dr. Bronstein’s extensive knowledge of our business and history, experience as a board member of biotechnology companies and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies contributed to our conclusion that he
What is the salary of Ben Bronstein?
As the Independent Director of Aldeyra Therapeutics Inc, the total compensation of Ben Bronstein at Aldeyra Therapeutics Inc is $135,515. There are 8 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.
How old is Ben Bronstein?
Ben Bronstein is 70, he's been the Independent Director of Aldeyra Therapeutics Inc since 2010. There are 1 older and 13 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.
What's Ben Bronstein's mailing address?
Ben's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.
Insiders trading at Aldeyra Therapeutics Inc
Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... és Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
What does Aldeyra Therapeutics Inc do?
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
What does Aldeyra Therapeutics Inc's logo look like?
Complete history of Ben Bronstein stock trades at Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc executives and stock owners
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Brady,
President, Chief Executive Officer, Director -
Joshua Reed,
Chief Financial Officer -
David McMullin,
Chief Commercial Officer -
Dr. Todd C. Brady M.D., Ph.D.,
CEO, Pres & Director -
Joshua Reed M.B.A.,
Chief Financial Officer -
Richard Douglas,
Independent Chairman of the Board -
Martin Joyce,
Independent Director -
Jesse Treu,
Independent Director -
Ben Bronstein,
Independent Director -
Gary Phillips,
Independent Director -
Neal Walker,
Independent Director -
Scott Solomon,
IR Contact Officer -
Nancy Miller-rich,
Independent Director -
Stephen Machatha,
Senior Vice President, Technical Operations -
James Gow,
Senior Vice President - Clinical Development -
Bruce Greenberg CPA, M.B.A.,
VP & Controller -
Dr. Stephen G. Machatha Ph.D.,
Chief Devel. Officer -
Kelly Mizer,
VP of Commercial Strategy & Operations -
David J Clark,
Chief Medical Officer -
Advisors Llcedelman Josephp...,
-
C. Boyd Clarke,
Director -
Stephen J Tulipano,
Chief Financial Officer -
Scott Young,
Chief Operating Officer -
Bruce Greenberg,
See Remarks -
Advisors Llcperceptive Life...,
-
Partners Vi, L.P.Blair Jame...,
-
& Johnson Johnson & Johnson...,
-
Vi Associates, L.P.Blair Ja...,